These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21917632)

  • 1. Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice.
    Tajima S; Ikeda Y; Sawada K; Yamano N; Horinouchi Y; Kihira Y; Ishizawa K; Izawa-Ishizawa Y; Kawazoe K; Tomita S; Minakuchi K; Tsuchiya K; Tamaki T
    Am J Physiol Endocrinol Metab; 2012 Jan; 302(1):E77-86. PubMed ID: 21917632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron chelation inhibits NF-kappaB-mediated adhesion molecule expression by inhibiting p22(phox) protein expression and NADPH oxidase activity.
    Li L; Frei B
    Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2638-43. PubMed ID: 16973969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron chelation by deferoxamine prevents renal interstitial fibrosis in mice with unilateral ureteral obstruction.
    Ikeda Y; Ozono I; Tajima S; Imao M; Horinouchi Y; Izawa-Ishizawa Y; Kihira Y; Miyamoto L; Ishizawa K; Tsuchiya K; Tamaki T
    PLoS One; 2014; 9(2):e89355. PubMed ID: 24586712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zn/Ga-DFO iron-chelating complex attenuates the inflammatory process in a mouse model of asthma.
    Bibi H; Vinokur V; Waisman D; Elenberg Y; Landesberg A; Faingersh A; Yadid M; Brod V; Pesin J; Berenshtein E; Eliashar R; Chevion M
    Redox Biol; 2014; 2():814-9. PubMed ID: 25009783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NOX2 deficiency attenuates markers of adiposopathy and brain injury induced by high-fat diet.
    Pepping JK; Freeman LR; Gupta S; Keller JN; Bruce-Keller AJ
    Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E392-404. PubMed ID: 23233541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxytyrosol prevents PM
    Wang N; Ma Y; Liu Z; Liu L; Yang K; Wei Y; Liu Y; Chen X; Sun X; Wen D
    Free Radic Biol Med; 2019 Sep; 141():393-407. PubMed ID: 31279968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.
    Abdelrazik N
    Hematology; 2007 Dec; 12(6):577-85. PubMed ID: 17852442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferoxamine ameliorates hepatosteatosis via several mechanisms in ob/ob mice.
    Xue H; Chen D; Zhong YK; Zhou ZD; Fang SX; Li MY; Guo C
    Ann N Y Acad Sci; 2016 Jul; 1375(1):52-65. PubMed ID: 27447538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron chelation with deferoxamine: comparing the results of a critical pathway to a national survey.
    DeSwarte-Wallace J; Groncy PK; Finklestein JZ
    J Pediatr Hematol Oncol; 1999; 21(2):136-41. PubMed ID: 10206460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo.
    Wang Y; Liu Z; Lin TM; Chanana S; Xiong MP
    Int J Pharm; 2018 Mar; 538(1-2):79-86. PubMed ID: 29341909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy.
    Porter JB; Abeysinghe RD; Marshall L; Hider RC; Singh S
    Blood; 1996 Jul; 88(2):705-13. PubMed ID: 8695819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deferoxamine B but not deferoxamine G1 inhibits cytokine production in murine bone marrow macrophages.
    Autenrieth IB; Bohn E; Ewald JH; Heesemann J
    J Infect Dis; 1995 Aug; 172(2):490-6. PubMed ID: 7622893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dietary iron restriction inhibits progression of diabetic nephropathy in db/db mice.
    Ikeda Y; Enomoto H; Tajima S; Izawa-Ishizawa Y; Kihira Y; Ishizawa K; Tomita S; Tsuchiya K; Tamaki T
    Am J Physiol Renal Physiol; 2013 Apr; 304(7):F1028-36. PubMed ID: 23389454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferoxamine therapy in high-ferritin diabetes.
    Cutler P
    Diabetes; 1989 Oct; 38(10):1207-10. PubMed ID: 2792574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletion of p22
    Lob HE; Song J; Hurr C; Chung A; Young CN; Mark AL; Davisson RL
    JCI Insight; 2017 Jan; 2(2):e87094. PubMed ID: 28138551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A long-term high-fat diet changes iron distribution in the body, increasing iron accumulation specifically in the mouse spleen.
    Yamano N; Ikeda Y; Sakama M; Izawa-Ishizawa Y; Kihira Y; Ishizawa K; Miyamoto L; Tomita S; Tsuchiya K; Tamaki T
    J Nutr Sci Vitaminol (Tokyo); 2015; 61(1):20-7. PubMed ID: 25994136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferoxamine regulates neuroinflammation and oxidative stress in rats with diabetes-induced cognitive dysfunction.
    Zeinivand M; Nahavandi A; Zare M
    Inflammopharmacology; 2020 Apr; 28(2):575-583. PubMed ID: 31786804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron-chelating agents attenuate NMDA-Induced neuronal injury via reduction of oxidative stress in the rat retina.
    Sakamoto K; Suzuki T; Takahashi K; Koguchi T; Hirayama T; Mori A; Nakahara T; Nagasawa H; Ishii K
    Exp Eye Res; 2018 Jun; 171():30-36. PubMed ID: 29530811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.